The evolutionarily conserved WNT-β-catenin pathway initiates a signalling cascade that is crucial during both normal embryonic development and throughout the life of the organism in virtually every tissue and organ system. It is an enormously complex and ancient pathway that dates back to the first anaerobic metazoans. The WNT-β-catenin network was first identified in 1982 with the discovery of the proto-oncogene Int1 (now known as Wnt1) in mice 1 . Five years later, the segment polarity gene wingless, the Drosophila melanogaster homolog of Int1, was cloned and shown to be required for proper wing formation 2 . Injection of INT1 caused axis duplication in Xenopus laevis embryos, thereby demonstrating the highly conserved nature of the pathway 3 . Since then, the crucial role of WNT-β-catenin signalling in development has been demonstrated in an array of organ systems, including the brain, eye, spinal cord, bone, cartilage, skin, lung, teeth, mammary gland, gut, heart, liver, kidney, pancreas and the haematopoietic and reproductive systems 4,5 . Moreover, WNT signalling has crucial roles in adulthood: in the daily processes of tissue homeostasis and regeneration in the hair and skin 6 , in the maintenance of intestinal homeostasis 7 and in haematopoiesis 8, 9 . Furthermore, WNT-β-catenin signalling is involved in liver and lung repair after injury [10] [11] [12] and in adult neurogenesis 13 . WNT signalling also has important roles in cell migration 14, 15 , genetic stability and instability [16] [17] [18] , and apoptosis 19, 20 . Given this vast array of functions, the WNT signalling cascade must therefore be tightly regulated to maintain proper tissue homeostasis, and aberrant WNT signalling has been associated with many types of cancer [21] [22] [23] as well as with other diseases including fibrosis 24, 25 , metabolic disease 26 and neurodegenerative disorders [27] [28] [29] .
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The significant role of aberrant WNT signalling in disease has engendered substantial efforts into the development of therapeutic approaches to target this pathway. However, a number of factors have thwarted progress in this field. First, the WNT signalling cascade is bewilderingly complex; there are 19 WNT ligands and more than 15 receptors and co-receptors distributed over seven protein families in mammals 30 . Yet, this represents only the tip of the iceberg with regard to the difficulty in attempting to develop safe and effective specific therapeutics targeting the WNT pathway. For example, in addition to classical canonical WNT-induced activation of β-catenin-TCF (T-cell factor) transcriptional complexes, WNT proteins can elicit a variety of alternative responses, often grouped together as non-canonical WNT signalling 31 . Crosstalk from various non-WNT factors has also been reported to modulate nuclear β-catenin accumulation, as discussed in more detail below.
The ability to target the WNT signalling pathway offers enormous promise; however, like the sword of Damocles, substantial risks and concerns are ever present with regard to the targeting of such a crucial pathway in stem cell maintenance and tissue homeostasis. With this in mind, here we review recent efforts to modulate the WNT signalling cascade and critically analyse therapeutic approaches that are at various stages of development (FIG. 1) . Drugs that interfere with β-catenin interactors:
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WNTs are secreted, cysteine-rich glycoproteins that act as short-range ligands to locally activate receptormediated signalling pathways 30 . The hallmark of this pathway is that it activates the transcriptional activity of the multifunctional armadillo repeat-containing protein β-catenin, which is the key mediator of WNT signalling. β-catenin dynamically localizes to multiple subcellular locations, including adherens junctions where it contributes to cell-cell contacts, the cytoplasm where its levels are tightly controlled, and the nucleus where it is involved in transcriptional regulation and chromatin modifications 34, 35 . WNT morphogens are the central extracellular regulators of β-catenin dynamics; however, several other signalling cascades can also influence β-catenin dynamics, including hepatocyte growth factor (HGF; also known as scatter factor), prostaglandins, protein kinase A (PKA), E-cadherin, hypoxia, and so on [36] [37] [38] 
. The cytoplasmic pool of β-catenin is tightly regulated via phosphorylation by the 'destruction complex' , which includes glycogen synthase kinase 3β (GSK3β), casein kinase 1α (CK1α), the scaffold protein AXIN and the tumour suppressor adenomatous polyposis coli (APC), among others 39 . In the absence of WNT signalling, phosphorylation marks cytoplasmic β-catenin for ubiquitylation and proteasomal degradation 40 . A key step in the activation of WNT target genes is the formation of a complex between β-catenin and members of the TCF/LEF (lymphoid enhancer factor) family of transcription factors 41, 42 . To generate a transcriptionally active complex, β-catenin-TCF recruits the transcriptional co-activator CREB-binding protein (CBP) or its closely related homologue E1A-associated protein p300, as well as other components of the basal transcription machinery 43, 44 . The WNT-β-catenin signalling cascade has crucial roles in cell fate, proliferation, survival and migration. In the absence of extracellular WNT glycoproteins, a destruction complex -including the proteins adenomatous polyposis coli (APC), glycogen synthase kinase 3β (GSK3β) and AXIN -phosphorylates β-catenin, targeting it for ubiquitylation and proteasomal degradation. The binding of WNTs to Frizzled receptors and the co-receptors LRP5 (low-density lipoprotein receptor-related protein 5) and LRP6 relays a signal through Dishevelled (DVL), which results in inhibition of the destruction complex and nuclear entry of β-catenin. In the nucleus, β-catenin acts as a bridge between members of the T cell factor (TCF) family of transcription factors and the basal transcriptional apparatus via co-activators (CREB-binding protein (CBP), E1A-associated protein p300, the co-activator Pygopus (PYGO), B cell lymphoma 9 (BCL-9), and so on). Over the past decade, numerous studies have identified inhibitors at various points along the pathway, a few of which have recently entered clinical trials. These are discussed in detail within the main text. CK1α, casein kinase 1α; CRD, cysteine-rich domain; MBOAT, membrane-bound O-acyltransferase.
It is now clear that in addition to WNT-β-catenindependent WNT signalling (often referred to as 'canonical' signalling) (FIG. 1) , there are β-catenin-independent outcomes (often referred to as 'non-canonical' signalling) within the WNT signalling cascade. It is worth noting that although designating WNT signalling pathways as either canonical or non-canonical may simplify their discussion, the reality is that crosstalk between these two 'arms' of the pathway, as well as other players, stimulates complex nonlinear networks (BOX 2); however, a detailed discussion of this is beyond the scope of this Review. For instance, HGF induces β-catenin stabilization in colorectal cancer cells via the MET-dependent inhibitory phosphorylation of Ser9 of GSK3β 45 . Tyrosine phosphorylation of β-catenin by BCR-ABL in chronic myeloid leukaemia also leads to its stabilization and nuclear signalling activity by decreasing its binding affinity to E-cadherin 46 . β-catenin is a member of the large armadillo protein family, which consists of three subfamilies: the p120 subfamily, the beta subfamily (comprising β-catenin and junction plakoglobin (also known as γ-catenin)) and the more distant alpha subfamily. Junction plakoglobin is involved in WNT-catenin signalling, even in the absence of β-catenin [47] [48] [49] . Further adding to the complexity, β-catenin can bind to a broad spectrum of transcription factors other than TCF/LEF, thereby modulating a plethora of downstream biological processes including pluripotency, epithelial-to-mesenchymal transition, oxidative stress and melanocyte development 50 . The strict definition of canonical WNT signalling -using the TOP-Flash reporter assay as a read-out of β-catenin-TCF activity -might not capture all the important transcriptional changes caused by activated WNT signalling. A broader view of the nuclear role of β-catenin as a partner for many transcription factors (for example, forkhead box proteins (FOXOs), nuclear receptors, SOX, SMAD, and so on), gives a more complete picture 50 . The broader role of WNT-β-catenin transcription must be taken into account when considering therapeutic strategies.
Role of the WNT-β-catenin pathway in disease Given the crucial role of WNT signalling in virtually every organ system in normal homeostasis and repair after injury, it is not surprising that aberrant regulation of this signalling cascade is associated with an array of diseases. Beyond having an unequivocal role in multiple malignancies 25, 51 , aberrant WNT signalling apparently plays an important part in various other diseases, including neurological diseases, inflammatory and fibrotic disease, and disorders of endocrine function and bone metabolism in adults [52] [53] [54] . However, the ubiquitous nature of WNT signalling and its pleiotropic effects also raise considerable concern over the use of pathway agonists or antagonists to treat any particular indication, particularly in a chronic setting. The involvement of WNT signalling in various diseases is outlined below.
Cancer. Aberrant regulation of WNT signalling has emerged as a recurrent theme in cancer biology 23, 51 . Constituents of WNT signalling can basically be characterized as either positively or negatively acting components, where the negatively acting components that principally act to suppress tumorigenesis are found mutated or in a loss-of-function status in cancer, whereas the positive components are activated 51 . The discovery in 1991 that mutations in the tumour suppressor APC were associated with the vast majority of sporadic colorectal cancers via aberrant activation of WNT signalling provided considerable impetus to attempt to therapeutically target this pathway 55, 56 . Germline defects in APC cause familial adenomatous polyposis, in which affected individuals develop hundreds of polyps in the large intestine at an early age and ultimately progress to colorectal cancer with 100% penetrance 57 . Loss of function in both alleles of APC is required for tumorigenesis and is linked to the protein's ability to regulate β-catenin protein stability 58 as well as chromosomal stability 59 . APC is now noted as the most frequently mutated gene overall in human cancers 60, 61 . Mutations affecting the WNT pathway are not limited to colon cancer. For example, loss-of-function mutations in AXIN have been found Box 1 | Alternative signalling cascades affecting β-catenin dynamics
The nuclear entry of β-catenin and the subsequent transcriptional processes affected by β-catenin are classically controlled by the so-called canonical WNT signalling cascade. However, in reality there are a number of alternative signalling pathways that can induce the nuclear translocation of β-catenin and its subsequent participation in transcription. The process of epithelial-to-mesenchymal transition (EMT) involves the downregulation of E-cadherin, which normally binds to cytoplasmic β-catenin in a complex with α-catenin that stabilizes epithelial architecture 264 ; therefore, EMT is associated with the nuclear translocation of β-catenin 265 .
EMT is a hallmark of metastasis 266 and has also been linked to the generation of cancer stem cells and tumourinitiating cells 267 . A variety of receptor tyrosine kinases, including the receptors MET, FER, FYN and RON 268 , and non-receptor tyrosine kinases, including SRC 269 and ABL
270
, can also disrupt the interaction of E-cadherin with β-catenin, thereby enhancing T cell factor (TCF)-β-catenin transcription. Various G protein-coupled receptor signal transduction pathways can activate TCF-β-catenin signalling, including prostaglandin E 2 (PGE 2 ) via the PGE 2 receptor EP2 and EP4 subtypes 271 , PGF 2α via the PGF receptor 272 , leukotriene D 4 via the cysteinyl leukotriene receptors, as well as the activation of an array of G proteins such as Gα, Gα 12 and Gα 13 (REFS 273, 274) . Additionally, environmental conditions such as hypoxia 275 and high glucose levels 276 can activate TCF-β-catenin signalling. Therefore, numerous signalling molecules and cascades also influence β-catenin dynamics and TCF-β-catenin transcription [36] [37] [38] . in hepatocellular carcinomas, and oncogenic β-catenin mutations that were first described in colon cancer and melanoma 62 were subsequently found to occur in a variety of solid tumours 53 , including hepatocellular carcinomas 63 , thyroid tumours 64 and ovarian endometrioid adenocarcinomas 65 . Epigenetic silencing is also frequently observed to alter levels of expression of negative regulators of the WNT-β-catenin pathway. For example, methylation of genes that encode putative extracellular WNT antagonists, such as the secreted Frizzled-related proteins (SFRPs), has been described in colon, breast, prostate, lung and other cancers [66] [67] [68] [69] [70] . Increased expression of WNT ligands [71] [72] [73] or effector proteins, including Dishevelled (DVL), has also been described [74] [75] [76] . Tumour formation and progression has also been associated with aberrant β-catenin-independent WNT signalling 77 . However, even the simple notion that targeting aberrantly high WNT-β-catenin signalling in cancer would be universally beneficial has been called into question. For instance, although several studies have correlated increased WNT-β-catenin signalling in tumours with worse prognosis for patients with colorectal cancer [78] [79] [80] , elevated WNT signalling does not correlate with reduced patient survival in all types of cancer. As a case in point, in patients with melanoma, active WNT-β-catenin signalling -as judged by nuclear β-catenin in tumours -is associated with a lower proliferative index and correlates with a more favourable prognosis [81] [82] [83] . Moon and colleagues 23 have presented further evidence that WNT signalling can either promote or inhibit tumour initiation, growth, metastases and drug resistance in a cancerstage-specific and a cancer-type-specific manner. For example, in a mouse model of melanoma, overexpression of WNT3A results in a less aggressive disease phenotype with increased expression of melanocyte differentiation markers 84 . Genetic evidence also supports a crucial role for the levels of β-catenin signalling in dictating tissuespecific predisposition to APC-driven tumorigenesis 85 . Together, these studies further add to the challenges and complexity of developing safe and effective therapeutic agents targeting this complex cascade.
Neurological diseases. The importance of WNT signalling during embryonic development of the central nervous system is well established 86 . The WNT pathway also regulates nervous system patterning and the regulation of neural plasticity. WNTs also have a role in axon guidance as well as in influencing synapse formation 87 . Therefore, it is not surprising that aberrations in WNT signalling have been observed in neurological diseases in adulthood. For example, a Scottish family with a high incidence of schizophrenia, depression and bipolar disorder was found to carry a balanced chromosomal translocation involving the gene DISC1 (disrupted in schizophrenia 1) 88 . Subsequently, the protein product of DISC1 was found to have an important role in neural development and neural progenitor proliferation 89 . DISC1 directly interacts with and inhibits GSK3β activity, thereby enhancing β-catenin-mediated transcription 90 .
Neuroanatomical observations and functional magnetic resonance imaging (MRI) have indicated that a major pathological hallmark in autistic individuals may be a premature overgrowth of the cerebral cortex, hippocampus, amygdala and cerebellum [91] [92] [93] [94] . Interestingly, transgenic mice expressing a constitutively active form of β-catenin in neuronal precursor cells developed a grossly enlarged cerebral cortex, hippocampus and amygdala 95, 96 . Importantly, microdeletion and microduplication copy number variations of genes involved in the canonical WNT signalling pathway (for example, Frizzled 9 (FZD9), B cell lymphoma 9 (BCL9) or cadherin 8 (CDH8)) are found in patients with autism spectrum disorder. Association studies investigating WNT2, DISC1, MET, dedicator of cytokinesis protein 4 (DOCK4) or Abelson helper integration site 1 (AHI1; also known as jouberin) have provided additional evidence that the canonical WNT pathway might be affected in autism 97 . The WNT signalling cascade has also been implicated in Alzheimer's disease. Presenilin proteins, which have been associated with early-onset Alzheimer's disease, are negative regulators of canonical WNT signalling 98 . Variant alleles in the WNT receptor LRP6 (low-density lipoprotein receptor-related protein 6) have been associated with Alzheimer's disease in population-based linkage analyses 99 . This suggests that multiple mechanisms leading to aberrant WNT-mediated regulation of adult neurogenesis may be associated with Alzheimer's disease [100] [101] [102] . As the underlying cause (or causes) of Alzheimer's disease have not been clearly elucidated, the mechanisms whereby aberrant WNT regulation may have a role in Alzheimer's disease are also not known. WNT signalling is involved in brain vascularization and blood-brain barrier formation 103 , in synaptogenesis 104 , in amyloid-β-induced neuroinflammation and neurotoxicity 105 , as well as in neuronal degeneration 106, 107 . Aberrant regulation of any or all of these processes could contribute to disease initiation and progression.
Box 2 | Non-canonical WNT signalling
The 'canonical' or β-catenin-dependent WNT signalling pathway has crucial roles in the regulation of diverse cell behaviours, including cell fate, proliferation and survival. However, a second non-canonical pathway exists, whose major effects seem to be β-catenin-independent in that there is no apparent stabilization of cytoplasmic β-catenin. The non-canonical pathway is more associated with differentiation, cell polarity and migration 277 . Pathways affected by non-canonical signalling include calcium-dependent and small GTPase-dependent signalling networks and the planar cell polarity (PCP) signalling pathway 278, 279 , a pathway by which cells receive positional identity. Non-canonical signalling can be initiated by WNT-Frizzled receptor interactions; alternatively, RYK and ROR receptor tyrosine kinases can also act as WNT receptors to activate β-catenin-independent signalling 32 . β-catenin-independent signalling can also regulate small GTPases, such as RHOA, RAC and cell division control protein 42 (CDC42), in a Dishevelled-dependent manner 280 . Non-canonical WNT-activated calcium flux results in the activation of various kinase cascades, including protein kinase C (PKC), calcium/calmodulin-dependent protein kinase II (CaMKII) and JUN N-terminal kinase (JNK), and activates both AP1-and nuclear factor of activated T cells (NFAT)-dependent transcription. Although dissection of the pathway into canonical and non-canonical components may be convenient for discussion purposes, the reality is that these are interacting and intersecting pathways that can coordinately regulate and orchestrate complex processes such as embryonic development, stem cell maintenance, tissue homeostasis and wound healing; moreover, when aberrantly regulated, they can be associated with tumorigenesis, metastasis and other diseases.
WNTs have also been implicated in neural tube defects. Dvl2-mutant mice are born with thoracic spina bifida and mice with mutations in both Dvl1 and Dvl2 have more severe neural tube defects 108 . Mutations in AXIN can result in incomplete closure of the neural tube or malformation of the head folds 109 . Aberrant LRP6 signalling (hypoactivity, hyperactivity or missense mutations in LRP6) can also cause neural tube defects [110] [111] [112] . Interestingly, it has been demonstrated that a mutation in LRP6 causes the crooked tail mutation in mice that exhibit neural tube defects, which can be ameliorated by dietary intake of folic acid 110 . The benefits of folic acid in preventing neural tube defects are well documented in human development, so understanding the role of WNT signalling in neurulation has important clinical implications.
Finally, WNTs have also been implicated in Williams syndrome, which is caused by a heterozygous microdeletion of approximately 20 genes on chromosome 7 (REF. 113 ). The FZD9 gene is within this chromosomal deletion in many patients. This neurodevelopmental disorder is characterized by an effusive personality, enhanced language ability, preserved social function, a high incidence of seizures and impaired spatial cognition 114 . Interestingly, Fzd9 -/-mice have neurodevelopmental defects in the dentate gyrus, visuospatial memory defects and a lowered seizure threshold 115 .
Fzd9
+/-mice, which have the same genotype for this gene as patients with Williams syndrome, have an intermediate form of this dysfunction 115 . Therefore, it is quite likely that loss of FZD9 is responsible for some of the cognitive symptoms observed in patients with Williams syndrome.
Osteoporosis. The WNT pathway is also crucial for bone formation in adults. For example, the WNT co-receptor LRP5 has been linked to osteoporosis pseudoglioma syndrome 116 , an autosomal recessive disorder in which individuals have low bone mass and abnormal eye vasculature, and are predisposed to developing skeletal fractures. By contrast, a gain-of-function point mutation in LRP5, G171V, has been associated with increased muscle mass and skeletal strength in humans 117 . A direct role for WNT-β-catenin signalling has been demonstrated in osteoblasts at multiple stages, including in the promotion of osteoblast differentiation from progenitors and in promoting osteoblast and osteocyte survival in vitro 118, 119 . In addition, β-catenin was found to regulate the expression of osteoprotegerin, an inhibitor of osteoclast differentiation in mature osteoblasts 120, 121 . Patients with sclerosteosis, who have high bone mass, were found to have homozygous mutations in the gene that encodes sclerostin (SOST), which is a circulating inhibitor of the WNT signalling pathway that acts to inhibit LRP5 function 122, 123 . Antibodies targeting scler ostin have been shown to increase the rate of bone formation and bone density in rats 124 . A clear link to bone metabolism was first established by the discovery that LRP5 mutations are associated with osteoporosis pseudo glioma syndrome, as mentioned above. Subsequently, patients with distinct types of hereditary diseases characterized by high bone mass were found to carry mutations in the LRP5 extracellular domain 117, 125 , which rendered them resistant to inhibition by sclerostin 126, 127 . Modulation of WNT signalling has emerged as a promising strategy for increasing bone density. Smallmolecule inhibitors of GSK3β increase bone mass, lower adiposity and reduce fracture risk in preclinical models. Neutralizing antibodies targeting the secreted WNT inhibitors Dickkopf 1 (DKK1), SFRP1 and sclerostin produce similar outcomes in animal models 128 . A sclerostin-specific monoclonal antibody, romosozumab (also known as AMG 785), is currently in Phase III trials for post-menopausal osteoporosis.
Although homozygous loss of SOST has not been associated with an increased risk of cancer in patients, additional follow-up studies will be required to determine the long-term effects of increasing WNT signalling, in particular relating to cancer risk. In this regard, a recent study of 170 long-term users of the GSK3 inhibitor lithium (where the mean duration of lithium exposure was 21.4 years) demonstrated a significantly higher standardized incidence ratio of renal cancer compared with the general population: 7.51 (95% confidence interval (CI); 1.51-21.95) and 13.69 (95% CI; 3.68-35.06) in men and women, respectively 129 . Whether this is WNT-related or not is unclear, as lithium has additional pharmacological effects beside WNT signalling activation via GSK3 inhibition. Furthermore, as discussed below in the section on ageing, several murine models of ageing and accelerated ageing have demonstrated enhanced WNT signalling.
Fibrosis.
Fibrosis is characterized by an excessive accumulation of extracellular matrix components, which disrupts the physiological tissue architecture, leading to the dysfunction of the affected organ 130 . Fibrosis in general has been suggested to account for approximately 45% of deaths in industrialized countries, thereby highlighting the great medical need for effective antifibrotic therapies 24 . Activated WNT-β-catenin signalling has been implicated in fibrosis in a number of organ systems, including the lungs, which indicates that this developmental pathway can be reactivated in adult tissues following injury 25, [131] [132] [133] . Specific small-molecule WNT modulation in several murine models of fibrosis (such as lung and kidney models) has proven to be extremely effective. Specific inhibition of the CBP-β-catenin interaction was shown to not only ameliorate but also to reverse late-stage fibrotic injury in murine models of both lung and kidney fibrosis 134, 135 . However, again the role of WNT signalling in fibrosis is not completely straightforward. Several studies using WNT reporter mice provided evidence that activation of β-catenin signalling is an early event in the lung epithelium during the development of experimental fibrosis 136, 137 , and four published studies -including our own -have provided evidence that inhibition of WNT-β-catenin signalling can attenuate fibrosis 134, 138, 139 . However, a recent publication demonstrated that Cre recombinase-mediated depletion of β-catenin from surfactant protein C-expressing alveolar epithelial type 2 (AT2) cells did not protect -but instead promoted -fibrosis in the same model 140 .
The fate of 'good' versus 'bad' β-catenin signalling in lung epithelial cells is most probably dictated by which cofactor β-catenin binds to: CBP or p300. This model predicts that inhibition strategies will need to regulate WNT-β-catenin signalling to a level necessary for alveolar repair without promoting the fibroproliferation associated with fibrosis 141 .
Regenerative medicine: myocardial infarction and epithelial repair. The adult mammalian heart has a limited capability for self-repair after myocardial infarction; thus, therapeutic strategies that improve post-infarct cardiac function are crucially needed. WNT signalling is required to direct crucial biological processes during cardiac development and is important in both the proliferation and differentiation of various stem/progenitor cell populations 142 . Indeed, the renewal and differentiation of Isl1 + cardiovascular progenitors are both controlled by the WNT-β-catenin pathway 143 . Modulation of the WNT signalling pathway provides a pharmacological target for regenerative signalling in damaged myocardial tissue. In this regard, small-molecule intervention in the WNT signalling pathway with either pyrvinium or ICG-001 (FIG. 1; TABLE 1) have proven to be beneficial for the treatment of myocardial infarction in rodent models 144, 145 . There are also other potential therapeutic benefits from WNT agonists in regenerative medicine, including WNTs and R-spondins -secreted proteins that potentiate WNT signalling through their interaction with their leucine-rich repeat-containing G protein-coupled receptors (LGRs) and the transmembrane E3 ubiquitin ligases RING finger protein 43 (RNF43) and zinc/RING finger protein 3 (ZNRF3) 146 (FIG. 2) . These proteins are potent stimulators of adult stem cell proliferation both in vitro and in vivo. Consequently, in principle they could both potentially prove to be valuable therapeutic agents for regenerative medicine. Just as WNT signalling is important in many aspects of embryonic development, the WNT-enhancing ability of R-spondins, together with their dynamic expression patterns in embryonic tissues, predicts pleiotropic roles for R-spondins during embryo genesis and also in adult stem cell homeostasis 147 . The in vivo therapeutic potential of R-spondins was initially described in a mouse model of inflammatory bowel disease 148 and subsequently for the amelioration of gastrointestinal syndrome induced by radiation 149 or intensive chemoradiotherapy 150 . Although acute in vivo use of WNT signalling activatorsWNTs, R-spondins or small molecules -to enhance stem cell proliferation may prove to be therapeutically beneficial, substantial concerns regarding their chronic in vivo use, as described previously in the section on osteoporosis, will need to be addressed before these approaches are likely to be clinically validated.
Autoimmune diseases: rheumatoid arthritis and colitis.
WNT signalling has been implicated in the development of the immune system for quite some time, and TCF1 (also known as HNF1α) and β-catenin are known to regulate T cell development and function 151 . However, the contributions of WNT signalling to adult immunity are only beginning to be realized. Studies in adult T cells have shown that the WNT effector TCF1 is required for the functional generation of memory CD8 + T cells [152] [153] [154] [155] . WNT signalling can also affect the differentiation of naive CD4 + T lymphocytes 156 . WNT-β-catenin signalling has also been implicated in the development of T regulatory (T Reg ) cells that are involved in autoimmune disease, as well as in cancer and infectious diseases . Interestingly, patients with rheumatoid arthritis exhibit higher expression of WNT and FZD genes in synovial membranes of affected joints compared with healthy individuals without rheumatoid arthritis 158 . Increased expression of WNT7B in human synovial cells has been shown to induce inflammatory cytokines such as interleukin-1β (IL-1 β), IL-6 and tumour necrosis factor (TNF) in patients with rheumatoid arthritis 159 . β-catenin-independent WNT5A signalling has also been implicated in the development of rheumatoid arthritis 159 . Recently, elevated levels of β-catenin have been shown to prevent the differentiation of T Reg cells and enhance T helper 17 (T H 17) commitment, which is potentially linked to both the pro-inflammatory state in colitis and to an increased risk of colon cancer development 160 . β-catenin is also upregulated in pro-inflammatory monocytes and in antigen-presenting cells 161 . WNT-β-catenin signalling may be a crucially important pathway associated with the pro-inflammatory tumour microenvironment in inflammation-driven malignancies 162 .
Disorders of endocrine function. WNT signalling also has crucial roles in various endocrine functions and has therefore been implicated in several endocrine disorders 163 . Although a detailed discussion of these roles is beyond the scope of this Review, key observations are discussed below.
WNT signalling is important in the regulation of insulin sensitivity and its dysregulation is implicated in the development of diabetes. In particular, WNT10B increases insulin sensitivity in skeletal muscle cells 164 . Overexpression of WNT5B induces adipogenesis. Decreased expression of β-catenin-independent WNT5B, which has been demonstrated in patients with type 2 diabetes, may increase susceptibility to type 2 diabetes 165 . Additionally, polymorphisms in the transcription factor TCF7L2 (also known as TCF4), are linked to increased susceptibility to type 2 diabetes 166 . Individuals with at-risk alleles of TCF7L2 exhibit impaired insulin secretion, and TCF7L2 in pancreatic β-cells appears to have a crucial role in glucose metabolism through the regulation of pancreatic β-cell mass 167 . Recently, researchers treated cadaver-derived intact human islets with conditioned medium from L-cells that constitutively produced WNT3A, R-spondin 3 and Noggin, to which inhibitors of RHO-associated protein kinase (ROCK) and RHOA were added to augment cell survival. This led to an approximately 20-fold increase in β-cell proliferation compared with glucose alone 168 . Importantly, treatment with this conditioned medium did not impair glucose-stimulated insulin secretion or decrease the insulin content of the cells. In transcriptome-wide gene expression profiling and follow-up signalling studies, the researchers showed that the conditioned media treatment . However, translation of this to an in vivo therapeutic strategy to expand human pancreatic β-cells could prove to be extremely difficult owing to the potential need for chronic administration and effects on non-target tissues.
Ageing. Although perhaps not a disease per se, ageing and an ageing population in general are creating major health and economic issues. It is clear that with age there is a decline in both the fidelity and efficiency of the homeostatic and repair processes in the body. This could be due to a decline in tissue stem cell populations (such as haematopoietic stem cells (HSCs) as well as stem cells in the skin). However, recent data indicate that there is a decrease in the 'effectiveness' of these stem cells to serve as a regenerative pool during homeostasis, and therefore repair processes decrease with age 169 . Interestingly, several mouse models of premature ageing and decreased effectiveness of repair after injury (that is, increased fibrosis) have demonstrated an increase in WNT signalling [170] [171] [172] . Epidemiological data demonstrate that the risk of developing cancer, fibrosis or neurodegeneration increases significantly with age, starting at approximately the age of 50. As previously discussed, these diseases have all been associated with aberrant WNT signalling. Again, the potential to ameliorate the ageing process by safely modulating WNT signalling, particularly within the stem/progenitor population, could have a major impact not only on health and disease but also on medical economics.
Challenges in drugging the WNT pathway
There are a number of issues that must be considered in the development of therapeutic strategies to modulate the WNT pathway. Therapeutic agents that target crucial developmental signal transduction pathways (that is, the WNT, Notch, Hedgehog and bone morphogenetic protein (BMP) pathways) can have devastating effects on embryonic patterning, as evidenced by the chemically induced onset of cyclopia in lambs by the Hedgehog inhibitor cyclopamine and also in children with severely shortened limbs owing to the effects of thalidomide. Furthermore, somatic stem cell homeostatic and regenerative processes after injury also utilize these same pathways for the generation of new tissue and the maintenance of the somatic stem cell niche.
WNT signalling, specifically involving WNT4, is also involved in the development of the female reproductive system. During mammalian embryogenesis, WNT4 is expressed in the gonads of both sexes before sex determination events take place and is subsequently downregulated in the male gonad. Inactivation of WNT4 in mice has revealed that it is important at several steps of female reproductive development 173 . Nevertheless, despite the teratogenic effects of Hedgehog inhibition and the potential risks associated with targeting a crucial pathway involved in stem cell regulation, on 30 January 2012 vismodegib (Erivedge; Curis/ Genentech) -a Smoothened antagonist that disrupts Hedge hog signalling -became the first drug to be approved by the FDA for the treatment of locally advanced and metastatic basal cell carcinoma. As a class, the Hedgehog inhibitors have multiple adverse effects, including muscle spasms and cramps, alopecia, dysgeusia, fatigue, weight loss and diarrhoea 174 . However, these adverse effects are largely reversible after treatment is stopped. Serious concerns about the use of Hedgehog inhibitors during pregnancy and early childhood development still exist. Given the crucial role of WNT signalling in homeostasis in multiple organ systems (the intestine, haematopoietic system, skin and hair, and so on), similar side effects, as well as others (for example, bone loss or breakage) may be anticipated. Therefore when considering the targeting of crucial developmental pathways that are utilized by both cancer stem cells as well as normal somatic stem cells, the 'Jekyll and Hyde'-like potential behaviour of this class of therapeutic agents remains an ever-present issue 175 .
Agonists or antagonists: is that the question? It was originally believed that the choice of agonist versus antagonist, in particular for the treatment of oncologic malignancies, was relatively straightforward. However, the notion that universally antagonizing WNT-β-catenin signalling in cancer would be beneficial has been called into question 23 , as elevated WNT signalling does not correlate with reduced patient survival in all types of cancer.
WNT signalling appears to have an important role in neuroprotection and neural regeneration after brain injury, and enhanced WNT-β-catenin signalling is present in newly derived glial progenitors and astrocytes in a model of traumatic brain injury 176 . However, AXIN2, a WNT target gene that negatively regulates the pathway by promoting β-catenin degradation, was found to be expressed in immature oligodendrocyte progenitor cells in white matter lesions of human newborns with neonatal hypoxic-ischaemic and gliotic brain damage, as well as in active multiple sclerosis lesions in adults 177 . AXIN2 is essential for normal remyelination, and the small molecule XAV939, which inhibits tankyrase and thereby inhibits WNT signalling (FIG. 1; TABLE 1 ), stabilized AXIN2 levels in oligodendrocyte progenitor cells from the brain and spinal cord and accelerated their differentiation and remyelination after hypoxic and demyelinating injury 177 . We are therefore left with a conundrum: what do we need to do to treat these various indications in which WNT signalling apparently has an important role? Do we need to increase or decrease WNT signalling Frizzled and low-density lipoprotein receptor-related proteins (LRPs) on the surface of stem cells bind WNTs to regulate the nuclear translocation of β-catenin and activation of its transcriptional role in stem cell gene expression via recruitment of the kynurenine aminotransferase 3 (KAT3) co-activators CREB-binding protein (CBP) or E1A-associated protein p300 (part a). Enzymatic interaction of the transmembrane E3 ligases RING finger protein 43 (RNF43) and zinc/RING finger protein 3 (ZNRF3) can -through a negative feedback loop -lead to abrogation of WNT signalling via endocytosis of the Frizzled-LRP complex (part b). However, when R-spondin is present (as in part a) and recruited to leucine-rich repeat-containing G protein-coupled receptor 4 (LGR4) and LGR5, RNF43 and ZNRF3 interact with R-spondin, resulting in membrane clearance of the complex and the potentiation of WNT signalling. WNT signalling is important for proliferation and maintenance of potency as well as the differentiation of stem cells. to achieve a beneficial therapeutic effect? Or is it that aberrations in WNT signalling cannot be targeted using a single universal strategy, but rather that the clinical decisions will need to be made on a personalized basis? Why is there so much debate and controversy surrounding this topic?
Briefly, we believe that the problem is partly due to the following three reasons. The first is the multiple ways in which WNT signalling is read out (such as nuclear β-catenin levels, reporter assays and endogenous gene expression), which are highly cell-type dependent. The second is that the role of transcriptionally active nuclear β-catenin is highly underestimated by some of these readouts (for example, TOP-Flash), as β-catenin binds to a broad spectrum of transcription factors other than TCF/LEF and can modulate a plethora of downstream biological processes 50 . Last, and most importantly, WNT signalling is temporal and so during the processes of development, normal homeostasis or regeneration and repair, both the activation and subsequent diminution of WNT signalling are required, as highlighted by the essential roles of negative feedback loops (for example, AXIN2 expression) in the normal developmental and reparative programmes.
Our view, which is now beginning to be borne out in clinical trials with the specific CBP-β-catenin antagonist PRI-724, is that fixing aberrant WNT signalling must take into account the disparate effects of this pathway. In its simplest form, the roles of WNT in cell proliferation versus differentiation -symmetric versus asymmetric differentiation in stem/progenitor populations -must be balanced (BOX 3; FIG. 3) . Thus for the optimum therapeutic effect, a fine balance between these two dichotomous arms of the WNT signalling pathway needs to be maintained.
Crosstalk with the WNT pathway "No man is an island", and similarly no pathway can be modulated without affecting others. For example, a number of growth factor pathways can activate β-catenin signalling independently of WNTs, via activation of both their receptor and non-receptor tyrosine kinases
HGF, via activation of its receptor tyrosine kinase MET, mediates the phosphorylation of Tyr654 and Tyr670 of β-catenin, thereby inducing its dissociation from E-cadherin 178 . Similarly, Tyr142 and Tyr654 phosphorylation by FMS-like tyrosine kinase 3 (FLT3) leads to the dissociation of β-catenin from its complex with E-cadherin 179 . Phosphorylation of Tyr654 also enhances the binding of β-catenin to TCF4, further synergizing to enhance WNT-β-catenin signalling 180 . Not surprisingly, therefore, both the tyrosine kinase inhibitor imatinib (Gleevec; Novartis) and the small molecule PHA665752, which inhibits MET-mediated phosphorylation, have been shown to reduce WNT-β-catenin signalling 181, 182 . In addition, as previously alluded to, WNTs collaborate with various other key developmental pathways 183, 184 , in particular in stem and progenitor populations (FIG. 2) . Consistent with this extensive interwoven network, various small-molecule inhibitors of these pathways, including inhibitors of Notch and the mitogen-activated protein kinase (MAPK) pathway 185, 186 , indirectly affect WNT signalling. The WNT and RAS signalling cascades have been observed to synergistically contribute to tumour initiation and development in a number of transgenic mouse tumour models, including colon 187 , intestine 188 and liver 189 tumours. The convergence of these signalling pathways upregulates the expression of various genes (that is, cyclooxygenase 2 (COX2), MYC and IL8) that promote tumorigenesis [190] [191] [192] . Interestingly, monoallelic expression of an activating KRAS mutation in the mouse intestine has no phenotype but can promote tumorigenesis in APCdeficient mice 188 . Crosstalk between the WNT and Notch pathways has been implicated in an array of developmental processes, including intestinal homeostasis 193 , vascular remodelling 194 and somitogenesis 195 . We have also demonstrated that small-molecule antagonists of phosphatases and kinases can maintain mouse and human embryonic stem cell pluripotency in a WNTdependent fashion 196, 197 . Inhibition of the protein phosphatase 2A (PP2A) regulatory subunits PR72 and PR130 using the small molecule IQ-1 maintained pluripotency in murine embryonic stem cells in a WNT-dependent manner 196 . Similarly, the small molecule ID-8, an inhibitor of dual specificity YAK1-related kinases (DYRKs), allows for long-term WNT-mediated maintenance of human embryonic stem cells 197 . Salinomycin, an antibiotic potassium ionophore, was reported to act as a selective inhibitor of epithelial-to-mesenchymal transition and induce cytotoxicity in breast cancer stem cells 198 . Subsequently, it was shown that salinomycin, as well as another potassium ionophore, nigericin, blocked the phosphorylation of the WNT co-receptor LRP6 and induced its degradation, thereby downregulating WNT signalling 199 .
Nonspecific WNT pathway modulators Therapeutic agents that specifically target the WNT pathway have only recently entered clinical trials, although a few FDA-approved drugs do affect WNT signalling, albeit nonspecifically. Lithium salts have been used clinically for decades to treat psychiatric disorders such as manic depression. Lithium, among its multiple pharmacological actions, inhibits the constitutively active kinase GSK3, thereby stabilizing β-catenin and activating WNT signalling 200 . Non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin and sulindac, as well as the selective COX2 inhibitor celecoxib (Celebrex; Pfizer), inhibit the activity of COX, a key enzyme in the arachidonic acid cascade (TABLE 1) . Various experimental and epidemiological studies in humans have suggested that aspirin and other NSAIDs (for example, sulindac; see TABLE 1) have chemopreventive effects mainly in colon cancer [201] [202] [203] [204] [205] [206] [207] . Increased COX-generated prostaglandin E 2 (PGE 2 ) suppresses β-catenin degradation, and so inhibition of the WNT-β-catenin signalling pathway is one of the potential mechanisms of action of NSAIDs 208, 209 . NSAIDs have been demonstrated to reduce polyp formation in patients with familial adenomatous polyposis, which is associated with autosomal dominant mutations in the APC gene and the activation of WNT-β-catenin signalling 201, 210 . Vitamins, notably retinoids, which are synthesized from vitamin A in the body, are used in some forms of cancer therapy (notably acute promyelocytic leukaemia) and also in chemoprevention. The active form of vitamin D, 1α,25-dihydroxyvitamin D 3 , and its synthetic derivatives have shown chemopreventive effects in animal models of colorectal and breast cancers. Although the mechanism by which vitamins inhibit the WNT-β-catenin signalling pathway is not fully elaborated, it has been suggested that activated nuclear receptors for vitamins interact with β-catenin and compete with TCFs for the transcriptional co-activators p300 and CBP 211, 212 ( FIG. 1) . Recently, it has also been suggested that both vitamin A and vitamin D might induce inhibitory proteins of the WNT-β-catenin signalling pathway; for example, retinoids may induce Disabled homolog 2 (DAB2), whereas vitamin D may induce and DKK1 and DKK4 Polyphenols are a group of chemicals that are found in plants and are characterized by the presence of more than one phenol unit or building block per molecule. Several polyphenols, such as quercetin, epigallocatechin-3-gallate (EGCG), curcumin and resveratrol (TABLE 1) , have been implicated as inhibitors of the WNT-β-catenin signalling pathway, but the mechanisms of action of these agents are not clear owing to their inherent lack of specificity and inhibitory effects on multiple pathways [214] [215] [216] [217] [218] . The redox capacities of this class of molecules may have a role in their ability to inhibit WNT signalling, as redox regulation of transcriptionincluding the WNT signalling cascade 219 -is relatively ubiquitous 220 . Other classes of drugs that can inhibit WNT signalling have been identified by screening libraries of FDAapproved drugs. For example, the anti-helminthic drug pyrvinium was identified as an agent that could potentiate the activity of CK1α, leading to enhanced degradation of β-catenin and the co-activator Pygopus as well as a reduction in WNT-β-catenin signalling 221 (FIG. 1; TABLE 1) .
In a mouse model of myocardial infarction, pyrvinium demonstrated improvements in cardiac remodelling 144 .
Molecularly targeted agents
In addition to the existing nonspecific modulators of WNT signalling, several molecularly targeted agents are being developed. Those reported to date can be classified into five classes: β-catenin-TCF antagonists; drugs that bind the PDZ domain of DVL; other mechanism-based inhibitors that principally target enzymes (for example, Porcupine, tankyrase and kinase inhibitors); biologics; and drugs that target WNT co-activators.
β-catenin-TCF antagonists.
Effectively inhibiting the protein-protein interaction between TCF and β-catenin via a small molecule is not a trivial task, as the binding affinity between these two large protein molecules (FIG. 2) . However there is no consensus as to whether WNT signalling is important for the proliferation and maintenance of potency (pluri-or multipotency) [281] [282] [283] or the differentiation of stem/progenitor cells 142, 284 . WNT-β-catenin signalling has been demonstrated to maintain pluripotency in embryonic stem cells 282 and is crucial for the expansion of neural progenitors, thereby increasing brain size 95 . Recently, a crucial role for β-catenin has been demonstrated in the maintenance of the expression of the key pluripotency transcription factor octamer-binding protein 4 (OCT4; also known as POU5F1) in a T cell factor (TCF)-independent fashion 285 . However, WNT-β-catenin signalling is also required for the neural differentiation of embryonic stem cells 286 and in fate-decision in neural crest stem cells 287 ; moreover, WNT3A has been reported to promote differentiation into the neural and astrocytic lineages by inhibiting neural stem cell maintenance 288 . Clearly, WNT-β-catenin signalling also has a crucial role in the lineage decision and commitment of stem cells. These dramatically different outcomes upon activation of the WNT signalling cascade have fuelled enormous controversy concerning the role of WNT signalling in the maintenance of potency and induction of differentiation.
WNT and cancer stem cells
The similarities between normal adult somatic stem cells and cancer stem cells (CSCs) suggest that the same signalling pathways that are involved in regulating somatic stem cell maintenance are also involved in the regulation of CSCs [289] [290] [291] . CSCs exist in an array of tumour types, including leukaemias as well as brain, breast, prostate and colon cancers, and are associated with disease recurrence, multidrug resistance and metastasis 292 . CSCs express similar markers and exhibit cellular behaviours that are highly reminiscent of somatic stem cells. In addition to WNT signalling, a number of crucial pathways are involved in maintenance or loss of potency in stem cells (that is, the Notch, Hedgehog, transforming growth factor-β (TGFβ)-BMP, JAK-STAT, FGF-MAPK-PI3K (phosphoinositide 3-kinase) and Hippo pathways). Aberrant regulation of these same pathways leads to neoplastic proliferation in the same tissues. One conclusion that can be drawn is that there are multiple points of intersection and crosstalk, including feedback and feedforward loops, connecting the various signalling cascades that modulate 'stemness'. One major fundamental intrinsic difference between CSCs and long-lived normal somatic stem cells may be in their decision to divide asymmetrically or symmetrically 255, 293 . FIGURE 3 shows both asymmetric and symmetric modes of stem cell division. This, in principle, could provide a unique opportunity to therapeutically target CSCs without damaging the normal endogenous stem cell populations 255 . Clearly, successful therapeutic manipulation of endogenous somatic 'stemness' (normal or cancerous) will require precision to affect the desired transformation without having deleterious effects -particularly depletion -on the normal stem cell populations is apparently quite high (~20 nM). However, to date a number of very different approaches have been successful in identifying small-molecule inhibitors of this interaction.
In one of the earliest examples, a high-throughput enzyme-linked immunosorbent assay (ELISA) screen for the detection of the β-catenin-TCF interaction was utilized 222 . The primary screen of approximately 7,000 natural products and 45,000 synthetic compounds yielded eight compounds that dose-dependently inhibited complex formation (half-maximal inhibitory concentration (IC 50 ) <10 uM). Secondary assays generally demonstrated efficacy for the inhibition of WNT-specific reporter gene activity, colon cancer cell proliferation and β-catenin-induced axis duplication in Xenopus laevis embryos. Two structurally related compounds, PKF115-584 and CGP049090, (TABLE 1) proved to be the most effective. However, the molecular mechanism by which these compounds interfere with the WNT signalling pathway remains unclear. Interestingly, both PKF115-584 and CGP049090 also disrupt the β-catenin-APC interaction, implicating potential direct binding to β-catenin 222 . Subsequently, a cell-based high-throughput assay in D. melanogaster cells with a WNT-responsive luciferase reporter was used to screen 14,977 compounds, including known bioactive molecules, fungal extracts and members of a synthetic library. The primary screen yielded 34 hit compounds, three of which -iCRT3, iCRT5 and iCRT14 (FIG. 1; TABLE 1) -also disrupted the β-catenin-TCF interaction in vitro, inhibited the expression of WNT target genes and were cytotoxic to colorectal cancer cells 223 . Unfortunately, TOP-Flash inhibition in the same colorectal cancer cell lines, which would be a hallmark of a β-catenin-TCF interaction inhibitor, was not demonstrated. In another high-throughput screen of a large compound library, 2,4-diamino-quinazoline (TABLE 1) was identified as an inhibitor of the β-catenin-TCF4 pathway; this compound is currently in the lead optimization stage of development 224 . Although the actual molecular target for this class of inhibitors was not detailed, based on its molecular structure it is highly probable that it targets a kinase or kinases in the WNT-β-catenin pathway.
Trosset and colleagues 225 identified the synthetic compound PNU-74654 using structure-based virtual ligand (in silico) screening for a β-catenin-TCF antagonist. However, the biological activity of PNU-74654 was not reported (TABLE 1) . Another virtual screen, utilizing the 1990 small-molecule diversity set of the US National Cancer Institute to identify compounds that would bind to the armadillo repeat structure extracted from the X-ray structure of the β-catenin-TCF4 complex, identified a large set of compounds, among which the top-ranked compound was the organo-copper complex BC21 (TABLE 1) . Although a thorough validation of the mode of action of BC21 was not performed, it did reduce β-catenin-TCF reporter activity, the expression of WNT target genes and the viability of a colon cancer cell line (IC 50 = 15 μM) 226 . Despite the fact that these highthroughput screens and docking studies have yielded a number of hits, in general they are limited by relatively broad activity profiles and/or unclear mechanisms of action 227 . The α-helix is a common secondary structural motif mediating crucial interactions between protein-protein binding partners, including the β-catenin-BCL-9 and the β-catenin-TCF4 interfaces. Utilizing a stapled peptide approach, both the β-catenin-BCL9 (REF. 228 ) and the β-catenin-TCF4 interfaces have been targeted, yielding potent in vitro inhibitors (IC 50 ~10-20 nM), which displayed low micromolar cell-based inhibition 229 . The clinical utility of the stapled peptide class of molecules has yet to be established.
PDZ domain of DVL binders.
Another potential mechanism for decreasing WNT signalling is to target the PDZ domain of DVL. DVL is an essential protein in the WNT signalling cascade that transduces extracellular WNT signals to downstream components. DVL utilizes its PDZ domain, a common protein-protein interaction motif that recognizes short peptides, to bind to the carboxyterminal region of the Frizzled receptors. Three compounds (NSC 668036, FJ9 and 3289-8625) (FIG. 1;  TABLE 1) , which have the ability to block WNT signalling in vivo, were identified through in silico screening and nuclear magnetic resonance (NMR) spectroscopy approaches [230] [231] [232] . These compounds generally inhibit the Frizzled-PDZ interaction in the micromolar range in vitro. Porcupine and tankyrase inhibitors. In 2009, two reports were published describing WNT-β-catenin inhibitors that act on alternative molecular targets. Chen and colleagues 233 described several small-molecule IWRs (inhibitors of WNT response), such as IWR-1 (IC 50 = 180nM) (FIG. 1;  TABLE 1) , that stabilize the protein AXIN, and another group of compounds termed IWPs (inhibitors of WNT production), at least one of which (IWP-2; IC 50 = 27nM) inhibits the acyltransferase Porcupine, which is an essential protein for WNT secretion (FIG. 1; TABLE 1 ). Subsequently, Huang et al. described the WNT inhibitor XAV939, which induces the stabilization of AXIN by inhibiting the poly(ADP)-ribosylating enzymes tankyrase 1 and tankyrase 2 (REF. 234) (FIG. 1) . Tankyrases have been shown to interact with a highly conserved domain of AXIN and promote its ubiquitylation and degradation 234 . It was determined that IWR-1 also inhibits tankyrase 234 . Tankyrase inhibitors successfully curtail WNT-mediated cellular responses, which demonstrates that stabilization of AXIN is a potentially viable strategy for inhibiting the WNT-β-catenin signalling cascade. More recently, various additional potent and selective tankyrase and Porcupine inhibitors have been described 235 . Tankyrase 1 and tankyrase 2 are part of the larger family of poly(ADP-ribose) polymerase (PARP) enzymes. The development of more selective second-generation tankyrase inhibitors 235 is in progress. However, the full antitumour potential of even these analogues may not be realized owing to the intestinal toxicity associated with on-target inhibition of WNT-β-catenin signalling and cell proliferation in intestinal crypts, which was observed in preclinical models 236 . Loss-of-function mutations in the liver kinase B1 (LKB1; also known as STK11) tumour suppressor gene restrain the activity of WNT receptors (such as Frizzled), and Porcupine inhibitors counter deviant pathway activities driven by LKB1 loss of function in vitro. RNF43 is a gene encoding a transmembrane ubiquitin ligase. RNF43 antagonizes WNT signalling in adult stem cells by ubiquitylating Frizzled receptors, which leads to endocytosis of the WNT receptor. Conversely, binding of ZNRF3 or RNF43 to the receptors LGR4, LGR5 or LGR6, and simultaneously to R-spondin, blocks Frizzled ubiquitylation and enhances WNT signalling 146, 147, [237] [238] [239] . RNF43 has been suggested as a negative regulator of WNT signalling, and mutations in RNF43 have been identified in various tumours, including cystic pancreatic tumours. Interestingly, the Porcupine inhibitor LGK974 inhibited proliferation and induced differentiation in RNF43-mutant but not wild-type pancreatic cancer cells. The presence of RNF43 mutations may possibly be used as a predictive biomarker for patient selection, supporting the clinical development of Porcupine inhibitors in certain subtypes of cancer 240 .
Biological agents. Another approach that has received significant attention is the targeting of specific WNTs or WNT receptors that are aberrantly overexpressed in tumours. For example, intraperitoneal injections of WNT3A-neutralizing antibodies decrease proliferation and induce apoptosis in a mouse model of prostate cancer 241 . Antibodies targeting Frizzled receptors have also been shown be effective in various preclinical models, including those of breast, colon and liver cancer, and appear to preferentially spare normal tissue 242, 243 (FIG. 1) .
The monoclonal antibody OMP-18R5 (FIG. 1; TABLE 1) , which was initially identified by binding to FZD7, in fact interacts with five Frizzled receptors through a conserved epitope within the extracellular domain and blocks canonical WNT signalling induced by multiple WNT family members 244 . In patient-derived mouse xenograft models, OMP-18R5 inhibited the growth of a range of tumour types, reduced the fraction of cells that could seed new tumours and exhibited synergy with standard-of-care chemotherapeutic agents 244 .
WNT co-activator modulators. To generate a transcriptionally active complex, β-catenin recruits the transcriptional co-activator CBP or its closely related homologue p300, as well as other components of the basal transcriptional machinery, leading to the expression of a host of downstream target genes 4 . These two co-activators have long been considered as having largely redundant roles. Recent work has documented that CBP and p300 interact with hundreds of proteins in their roles as master orchestrators of transcription and, despite their high degree of homology, accumulating evidence indicates that CBP and p300 are not redundant but have definitive and unique roles both in vitro and in vivo [245] [246] [247] . Using the TOP-Flash reporter gene system in SW480 colon carcinoma cells, we identified ICG-001 as an inhibitor of β-catenin-TCF transcriptional activity from a library of 5,000 secondary-structure mimetics. ICG-001 (FIG. 1; TABLE 1 ) had an IC 50 value of 3 μM in this assay. Using an affinity chromatography approach, we identified and subsequently validated -using a gain-of-function and loss-of-function strategy -that ICG-001 binds specifically and with high affinity (~1 nM) to the co-activator CBP. Importantly, ICG-001 does not bind to the closely related homologue p300, despite the fact that these two co-activators are up to 93% identical with even higher homology at the amino acid level 248, 249 . We further demonstrated that selectively blocking the interaction between CBP and β-catenin with ICG-001 led to the initiation of a differentiation programme.
This led to the development of our model of differential co-activator usage, which highlights the distinct roles of the co-activators CBP and p300 in the WNT-β-catenin signalling cascade 101 . The crucial feature of the model is that the utilization of CBP induces a transcriptional programme that promotes proliferation and the maintenance of potency, whereas utilization of p300 leads to a transcriptional programme that initiates differentiation. Subsequently, we identified several small molecules (IQ-1 and ID-8) that selectively block the p300-β-catenin interaction, thereby increasing the CBP-β-catenin interaction, which maintains potency (plurior multipotency) in a variety of mouse and human stem cell populations 196, 197, 250, 251 . The therapeutic potential of the selective CBP-β-catenin antagonist ICG-001 has been examined in several preclinical tumour models, where it has demonstrated the ability to safely eliminate drug-resistant tumour-initiating cells [252] [253] [254] . Interestingly, CBP-β-catenin antagonists have also demonstrated efficacy in various injury models, including models of pulmonary and renal fibrosis 134, 135 as well as myocardial infarction 145 , which suggests that these antagonists can induce therapeutic differentiation without the subsequent cell elimination observed in cancer stem cell models. It appears that the differential effects of CBP-β-catenin antagonists on cancer stem cells versus normal somatic stem cells are cell intrinsic and not due to a differential ability of the drug to enter these two cell types. We proposed that CBP-β-catenin antagonists take advantage of the intrinsic propensity of cancer stem cells to increase their number of symmetric divisions at the expense of asymmetric divisions as a result of various mutations (for example, mutations in genes encoding the tumour suppressor p53 and phosphatase and tensin homolog (PTEN)). Normal endogenous long-term repopulating stem cells preferentially divide asymmetrically, with one daughter cell remaining in the niche and the other developing into a transient amplifying cell required for generating the new tissue involved in repair processes 255 . In principle, substantial concerns about specificity could be raised with regard to the use of small-molecule inhibitors that target a co-activator protein with perhaps as many as 500 molecular partners, including an array of transcription factors. However, these concerns have not been borne out either preclinically or clinically to date (see below). This is perhaps surprising at first. A full discussion of the many advantages of a small-molecule therapeutic that selectively targets the amino-terminus of CBP is beyond the scope of this Review 255 . However, we would like to point out a few salient features that all have a role: the extremely high biochemical selectivity of ICG-001 and PRI-724 for their molecular target; the disruption of only a small subset of CBP interactions; and the unique properties of the two KAT3 co-activators, CBP and p300, which evolutionarily diverged more than 500 million years ago. That being said, as ICG-001 is a CBP-catenin antagonist, by virtue of its binding to the N-terminus of CBP, its inhibitory effects go beyond the classical TCF-β-catenin antagonism for which it was originally screened in colorectal cancer cells 255 .
From bench to bedside: agents in the clinic
Targeting the WNT signalling pathway in the clinic using small-molecule therapeutics or even biologics is still in its infancy. Despite intensive investigation of the pathway and the unveiling of a multitude of potential therapeutic points of intervention in the pathway, as well as the identification of reagents that interfere with some of these targets, it is still unclear which approach will provide both clinical efficacy and safety.
Porcupine is a member of a 16-gene family of O-acyltransferases and it specifically palmitoylates WNTs, thereby enabling WNT secretion 53, 256 . Importantly, at a dose of 3 mg per kg per day for 14 days, which was sufficient to cause regression of WNT-driven tumours in rats, the Porcupine inhibitor LGK974 was well tolerated without abnormal histopathological findings in other WNT-dependent tissues (for example, the intestine).
LGK974 exhibited a 63% delay in tumour growth when administered at a dose of 3 mg per kg per day. At a dose of 20 mg per kg per day for 14 days, however, loss of intestinal epithelium was observed, which was consistent with the anticipated effects of disrupted WNT signalling in the intestine. From a clinical therapeutic standpoint, this study demonstrated a potential therapeutic window for the use of this class of inhibitors 257 . Recently, Novartis initiated a Phase I trial of LGK974 (IC 50 = 400 nM) (FIG. 1; TABLE 1 ) in a variety of malignancies (melanoma, breast cancer and pancreatic adenocarcinoma) that are associated with aberrant WNT signalling, with the primary objective of obtaining a maximum tolerated dose. This trial has not been completed and there is no publicly available information on the results. Again, concerns about on-target toxicity (that is, WNT inhibition and effects on intestinal stem cells, bone turnover and haematopoiesis) as well as off-target toxicity (that is, inhibition of other members of this class of O-acyltransferases or similar enzymes) will need to be carefully evaluated.
Two A total of 18 patients were treated in five dose escalation cohorts (0.5 and 1 mg per kg weekly; 0.5 mg per kg every 2 weeks; and 1 and 2.5 mg per kg every 3 weeks). The most common drugrelated adverse events included grade 1 and 2 fatigue, vomiting, abdominal pain, constipation, diarrhoea and nausea. The only potentially drug-related adverse events greater than or equal to grade 3 were dose-limiting toxicities of grade 3 diarrhoea and vomiting in one patient receiving 1 mg per kg every week, and one patient receiving 0.5 mg per kg every week had a bone fracture on day 110. There were three cases of prolonged stable disease in patients with neuroendocrine tumours.
The second OncoMed agent, OMP-54F28, is being co-developed with Bayer and is an Fc fusion protein with FZD8, which binds all WNT ligands (FIG. 1; TABLE 1 ). This clinical trial in solid tumours was initiated last year with the primary end point again being safety, and is currently still enrolling participants. Concerns about the potential deleterious effects of these agents on bone formation and turnover have been prospectively addressed in the trial design, with all participants receiving vitamin D 3 and calcium carbonate for 30 days after discontinuing OMP-54F28. Individuals will also be monitored during the study for the effects of the agent on bone density and turnover.
JW Pharmaceutical initiated a clinical study of the small molecule CWP232291, a prodrug form of a compound that is reported to target SRC-associated in mitosis 68 kDa protein (SAM68; also known as KHDRBS1) (TABLE 1) . SAM68 binds to the armadillo repeat domain of APC via its tyrosine-rich β-domain and regulates alternative splicing of TCF1 (REF. 259 ). Accumulation of the TCF1E splice variant strongly transactivates WNT target genes, thus SAM68-mediated pre-mRNA splicing may potentially modulate WNT signalling 259 . However, owing to the multi modular structure of SAM68, the apoptosis induced by this compound has been attributed to multiple effects, including the activation of nuclear factor-κB (NF-κB), alternative splicing of BCL-2 and WNT-mediated downregulation of the anti-apoptotic protein BIRC5 (baculoviral IAP repeat-containing protein 5; also known as survivin). A Phase Ia study to determine the maximum tolerated dose in patients with acute myeloid leukaemia was initiated in July 2011 and is still ongoing. No results related to this study have been publicly disclosed.
PRI-724 (FIG. 1; TABLE 1 ), a specific CBP and β-catenin antagonist developed by Prism Pharma and partnered with Eisai Pharmaceuticals, entered an open-label Phase Ia safety study in individuals with solid tumours, where the expression of the biomarker BIRC5 was measured by immunomagnetic real-time PCR in circulating tumour cells. We have previously shown that inhibition of the β-catenin-CBP interaction with ICG-001 potently inhibits BIRC5 gene transcription and expression. Furthermore, a chromatin immunoprecipitation assay confirmed that CBP is the crucial co-activator for TCF-β-catenin-mediated BIRC5 transcription 260 . The results of this trial were reported at the ASCO meeting in June 2013 (REF. 261 ). Overall, 18 patients were treated (dose escalation from 40 to 1,280 mg per m 2 per day) via continuous infusion for 7 days. PRI-724 had an acceptable toxicity profile, with only one dose-limiting toxicity of grade 3 reversible hyperbilirubinaemia. Downregulation of BIRC5 in circulating tumour cells correlated with increasing plasma drug concentrations 261 . Additional trials with PRI-724 are underway, including combination trials with a modified FOLFOX6 regimen for patients with refractory colorectal cancer, a Phase Ib trial for patients with refractory pancreatic cancer in combination with gemcitabine, and a Phase I/II trial for patients with haematological malignancies.
How can WNT antagonists and modulators most effectively be used therapeutically to treat cancer? Clinical experience with these agents is still quite limited at present; however, a few features that will, to some extent, determine the potential efficacy of an agent in a particular disease, are becoming apparent. These features include knowledge of where in the pathway the therapeutic agent acts -upstream (for example, LGK974, OMP18R5 or OMP-54F28) or downstream (for example, PRI-724) of β-catenin-induced transcription -and which mutations are present in the particular disease being targeted (for example, APC in colorectal cancer). For instance, upstream targeting agents are not likely to be efficacious in most colorectal cancers, as the APC mutations that are present in >80% of patients cause constitutive nuclear β-catenin translocation. Furthermore, targeting a particular point in the pathway may effectively target only a subset of patients. For example, in a battery of pancreatic cancer cell lines, LGK974 was efficacious only in cells carrying mutations in RNF43. This suggests that RNF43 mutations could be used as a predictive biomarker for patient selection, at least for this class of molecules in pancreatic cancer 240 . Preliminary results also indicate that combination therapy will be required to effectively treat most malignancies, at least in the majority of cases. This is consistent with the earlier discussion about WNT crosstalk with other pathways, such as the HGF-MET pathway. Several Phase Ib/IIa trials are underway in which a WNT antagonist or modulator is being used in combination with cytotoxic agents (for example, FOLFOX, gemcitabine, cytarabidine or a taxane derivative) or a targeted agent (for example, dasatinib).
The potential for WNT inhibitors and modulators to eliminate drug-resistant cancer stem cells and tumourinitiating cells via forced differentiation, thereby sensitizing resistant tumours to conventional therapy, is a particularly appealing strategy. Such an approach is currently being tested clinically in chronic myeloid leukaemia (both minimal residual disease and blast crisis) with PRI-724 in combination with the kinase inhibitor dasatinib. There are obvious concerns about combining cytotoxic agents with WNT inhibitors, which will have to be carefully monitored in the clinic. Interestingly, WNT modulation using CBP-catenin antagonists in preclinical models partially ameliorated the toxicity associated with chemotherapy 255 .
Future directions
More than 30 years after the ground-breaking discovery of WNT signalling and extensive investigation into this fundamental and highly evolutionarily conserved pathway, it is still unclear whether we will be able to successfully target the WNT signalling cascade for therapeutic purposes. Within the past several years, a number of agents, both small molecules and biologics, have entered clinical trials. Despite exciting preclinical data in various tumour and other disease models, it is still too early to know whether any of these therapeutic agents that specifically target the WNT pathway will be efficacious with an acceptable safety profile. It is already clear that successfully targeting aberrant WNT signalling in cancer, as well as in more chronic situations, will require a fine balancing act, wherein the 'dark side' of WNT signalling in disease can be abrogated without interfering with the crucial role of WNT signalling in tissue homeostasis (for example, in the intestinal epithelium, bone, and so on) and repair. Despite all of the potential safety concerns regarding the therapeutic targeting of the WNT signalling pathway, there is also tremendous excitement as our knowledge of this pathway -including its role in both normal physiology and pathophysiology and the discovery of potential new therapeutic points of intervention 262, 263 -continues to increase. The next several years should further clarify the answer to the question: "Can we safely target the WNT pathway?". 
